- MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMA September 25, 2024
- Positive results of phase II trial with MesoPher cell therapy in resected pancreatic cancer published in the Journal of Clinical Oncology July 9, 2024
- Amphera announces results of randomized phase II/III trial with MesoPher cell therapy in pleural mesothelioma, published in The Lancet Oncology June 19, 2024
- New video on results of Reactive phase II trial from Stichting Support Casper February 12, 2024
- MesoPher showed promising survival in peritoneal mesothelioma December 20, 2023
- Amphera announces a positive opinion of the European Medicines Agency on the granting of orphan medicinal product designation for MesoPher in pancreatic cancer June 6, 2023
- Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer April 27, 2023
- Amphera announces clinical updates of MesoPher cell therapy December 12, 2022
- Article on the Reactive study in resected pancreatic cancer published in Data in Brief August 4, 2022
- Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma August 1, 2022
- Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022 July 13, 2022
- Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer May 4, 2022
- First patient enrolled in ENSURE study in resected mesothelioma April 6, 2022
- Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma December 8, 2021
- Proof-of-concept Phase I clinical trial started to assess the safety and efficacy of CD40 agonist mitazalimab in combination with MesoPher in patients with progressive metastatic pancreatic cancer November 9, 2021
- DC vaccination-αCD40 combination therapy improves survival of pancreatic tumour-bearing mice June 11, 2021
- DENIM study presented at IMIG2021 May 19, 2021
- DENIM study presented as clinical trial in progress at the virtual WCLC2020 March 11, 2021
- Prof. Casper van Eijck presents first results of REACTIVE study November 26, 2020
- Article on DENIM study in Translational Lung Cancer Research (TLCR) July 12, 2019
- Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer May 21, 2019
- Amphera wins top ten list of most groundbreaking innovations in science May 16, 2019
- Amphera presents data of MesoPher and checkpoint inhibitor combination therapy to treat mesothelioma at AACR 2019 April 4, 2019
- Amphera recruits first patients to pivotal phase II/III study of MesoPher to treat pleural mesothelioma March 18, 2019
- ZonMW Parel awarded to prof dr Joachim Aerts for his research on dendritic cell immunotherapy MesoPher for mesothelioma March 15, 2018
- Successful DENIM Consortium Meeting at CHRU Lille March 11, 2018
- World Cancer Day 2018 – Presentation of Prof dr Joachim Aerts on dendritic cell immunotherapy for mesothelioma February 4, 2018
- Dendritic cell immunotherapy is safe and clinically active in mesothelioma December 9, 2016
- Amphera is moving to a new office June 19, 2014
- FDA Orphan Designation granted May 6, 2014
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok